Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) EPS (Weighted Average and Diluted) (2021 - 2025)

SAB Biotherapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.46 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 62.6% year-over-year to -$0.46; the TTM value through Dec 2025 reached -$2.32, up 36.96%, while the annual FY2025 figure was -$0.79, 78.53% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.46 in Q4 2025 per SABSW's latest filing, down from -$0.21 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.05 in Q1 2021 to a low of -$3.85 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.82, with a median of -$0.55 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 7400.0% in 2023, then surged 81.25% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.41 in 2021, then tumbled by 341.27% to -$1.81 in 2022, then crashed by 112.8% to -$3.85 in 2023, then soared by 68.05% to -$1.23 in 2024, then soared by 62.6% to -$0.46 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's EPS (Weighted Average and Diluted) are -$0.46 (Q4 2025), -$0.21 (Q3 2025), and -$1.09 (Q2 2025).